Clinical trial
Oblimersen and Doxorubicin in Treating Patients With Advanced Hepatocellular…
NCT00047229 · University Health Network, Toronto, Other · Completed
Key facts
| NCT number | NCT00047229 |
|---|---|
| Title | Oblimersen and Doxorubicin in Treating Patients With Advanced Hepatocellular Carcinoma (Liver Cancer) |
| Official title | A Phase II Study of G3139 in Combination With Doxorubicin in Advanced Hepatocellular Carcinoma |
| Lead sponsor | University Health Network, Toronto, Other |
| Collaborators | National Cancer Institute (NCI) NIH |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Liver Cancer |
| Intervention type | Biological, Drug |
| Interventions | oblimersen sodium, doxorubicin hydrochloride |
| Enrollment | 27 |
| Start date | Oct 1, 2002 |
| Primary completion | Jan 1, 2009 |
| Completion | Apr 1, 2009 |
| First posted | Jan 27, 2003 |
| Last update posted | Nov 8, 2017 |
| Countries | Canada |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: